OlympiA was a Phase 3, double-blinded, randomized trial evaluating the safety and efficacy of 12 months of adjuvant olaparib therapy versus placebo in high-risk, gBRCA-mutated, HER2-negative early breast cancer following definitive local treatment and adjuvant or neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.